<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Probiotics for maintenance of remission in ulcerative colitis - Iheozor-Ejiofor, Z - 2020 | Cochrane Library</title> <meta content="Probiotics for maintenance of remission in ulcerative colitis - Iheozor-Ejiofor, Z - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007443.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Probiotics for maintenance of remission in ulcerative colitis - Iheozor-Ejiofor, Z - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007443.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007443.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Probiotics for maintenance of remission in ulcerative colitis" name="citation_title"/> <meta content="Zipporah Iheozor-Ejiofor" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Lakhbir Kaur" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Morris Gordon" name="citation_author"/> <meta content="Patricia Anne Baines" name="citation_author"/> <meta content="Vasiliki Sinopoulou" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Anthony K Akobeng" name="citation_author"/> <meta content="Sidra Medicine" name="citation_author_institution"/> <meta content="aakobeng@sidra.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD007443.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/03/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007443.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007443.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007443.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; Colitis, Ulcerative [*therapy]; Mesalamine [therapeutic use]; Probiotics [adverse effects, *therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Remission Induction" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007443.pub3&amp;doi=10.1002/14651858.CD007443.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="uQyIsxpV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007443\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007443\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007443.pub3",title:"Probiotics for maintenance of remission in ulcerative colitis",firstPublishedDate:"Mar 4, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007443.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007443.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007443.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007443.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007443.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007443.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007443.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007443.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007443.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007443.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11052 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007443.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/appendices#CD007443-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/table_n/CD007443StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/table_n/CD007443StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Probiotics for maintenance of remission in ulcerative colitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information#CD007443-cr-0004">Zipporah Iheozor-Ejiofor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information#CD007443-cr-0005">Lakhbir Kaur</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information#CD007443-cr-0006">Morris Gordon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information#CD007443-cr-0007">Patricia Anne Baines</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information#CD007443-cr-0008">Vasiliki Sinopoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information#CD007443-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Anthony K Akobeng</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information/en#CD007443-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 March 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007443.pub3">https://doi.org/10.1002/14651858.CD007443.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007443-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007443-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007443-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007443-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007443-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007443-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007443-abs-0001" lang="en"> <section id="CD007443-sec-0001"> <h3 class="title" id="CD007443-sec-0001">Background</h3> <p>Ulcerative colitis is an inflammatory condition affecting the colon, with an annual incidence of approximately 10 to 20 per 100,000 people. The majority of people with ulcerative colitis can be put into remission, leaving a group who do not respond to first‐ or second‐line therapies. There is a significant proportion of people who experience adverse effects with current therapies. Consequently, new alternatives for the treatment of ulcerative colitis are constantly being sought. Probiotics are live microbial feed supplements that may beneficially affect the host by improving intestinal microbial balance, enhancing gut barrier function and improving local immune response. </p> </section> <section id="CD007443-sec-0002"> <h3 class="title" id="CD007443-sec-0002">Objectives</h3> <p>The primary objective was to determine the efficacy of probiotics compared to placebo, no treatment, or any other intervention for the maintenance of remission in people with ulcerative colitis. The secondary objective was to assess the occurrence of adverse events associated with the use of probiotics. </p> </section> <section id="CD007443-sec-0003"> <h3 class="title" id="CD007443-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, and two other databases on 31 October 2019. We contacted authors of relevant studies and manufacturers of probiotics regarding ongoing or unpublished trials that may be relevant to the review, and we searched ClinicalTrials.gov. We also searched references of trials for any additional trials. </p> </section> <section id="CD007443-sec-0004"> <h3 class="title" id="CD007443-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that compared probiotics against placebo or any other intervention, in both adults and children, for the maintenance of remission in ulcerative colitis were eligible for inclusion. Maintenance therapy had to be for a minimum of three months when remission has been established by any clinical, endoscopic,histological or radiological relapse as defined by study authors. </p> </section> <section id="CD007443-sec-0005"> <h3 class="title" id="CD007443-sec-0005">Data collection and analysis</h3> <p>Two review authors independently conducted data extraction and 'Risk of bias' assessment of included studies. We analysed data using Review Manager 5. We expressed dichotomous and continuous outcomes as risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). We assessed the certainty of the evidence using the GRADE methodology. </p> </section> <section id="CD007443-sec-0006"> <h3 class="title" id="CD007443-sec-0006">Main results</h3> <p>In this review, we included 12 studies (1473 randomised participants) that met the inclusion criteria. Participants were mostly adults. The studies compared probiotics to placebo, probiotics to 5‐aminosalicylic acid (5‐ASA) and a combination of probiotics and 5‐ASA to 5‐ASA. The studies ranged in length from 12 to 52 weeks. The average age of participants was between 32 and 51, with a range between 18 and 88 years. Seven studies investigated a single bacterial strain, and five studies considered mixed preparations of multiple strains. The risk of bias was high in all except three studies due to selective reporting, incomplete outcome data and lack of blinding. This resulted in low‐ to very low‐certainty of evidence. </p> <p>It is uncertain if there is any difference in occurrence of clinical relapse when probiotics are compared with placebo (RR 0.87, 95% CI 0.63 to 1.18; 4 studies, 361 participants; very low‐certainty evidence (downgraded for risk of bias, imbalance in baseline characteristics and imprecision)). It is also uncertain whether probiotics lead to a difference in the number of people who maintain clinical remission compared with placebo (RR 1.16, 95% CI 0.98 to 1.37; 2 studies, 141 participants; very low‐certainty evidence (downgraded for risk of bias, imbalance in baseline characteristics and imprecision)). </p> <p>When probiotics are compared with 5‐ASA, there may be little or no difference in clinical relapse (RR 1.01, 95% CI 0.84 to 1.22; 2 studies, 452 participants; low‐certainty evidence) and maintenance of clinical remission (RR 1.06, 95% CI 0.90 to 1.25; 1 study, 125 participants; low‐certainty evidence). It is uncertain if there is any difference in clinical relapse when probiotics, combined with 5‐ASA are compared with 5‐ASA alone (RR 1.11, 95% CI 0.66 to 1.87; 2 studies, 242 participants; very low‐certainty evidence (downgraded due to risk of bias and imprecision)). There may be little or no difference in maintenance of remission when probiotics, combined with 5‐ASA, are compared with 5‐ASA alone (RR 1.05, 95% CI 0.89 to 1.24; 1 study, 122 participants; low‐certainty evidence). </p> <p>Where reported, most of the studies which compared probiotics with placebo recorded no serious adverse events or withdrawals due to adverse events. For the comparison of probiotics and 5‐ASA, one trial reported 11/110 withdrawals due to adverse events with probiotics and 11/112 with 5‐ASA (RR 1.02, 95% CI 0.46 to 2.25; 222 participants; very low‐certainty evidence). Discontinuation of therapy was due to gastrointestinal symptoms. One study (24 participants) comparing probiotics combined with 5‐ASA with 5‐ASA alone, reported no withdrawals due to adverse events; and two studies reported two withdrawals in the probiotic arm, due to avascular necrosis of bilateral femoral head and pulmonary thromboembolism (RR 5.29, 95% CI 0.26 to 107.63; 127 participants; very low‐certainty evidence). </p> <p>Health‐related quality of life and need for additional therapy were reported infrequently.</p> </section> <section id="CD007443-sec-0007"> <h3 class="title" id="CD007443-sec-0007">Authors' conclusions</h3> <p>The effectiveness of probiotics for the maintenance of remission in ulcerative colitis remains unclear. This is due to low‐ to very low‐certainty evidence from poorly conducted studies, which contribute limited amounts of data from a small number of participants. Future trials comparing probiotics with 5‐ASA rather than placebo will better reflect conventional care given to people with ulcerative colitis. Appropriately powered studies with a minimum length of 12 months are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007443-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007443-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007443-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007443-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007443-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007443-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007443-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007443-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007443-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007443-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007443-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007443-abs-0002" lang="en"> <h3>Probiotics for maintenance of remission in ulcerative colitis</h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to find out whether probiotics can maintain remission in people with ulcerative colitis. We collected and analysed data from 12 studies with a total of 1473 people to answer this question. </p> <p><b>Key messages</b> </p> <p>The question on whether probiotics can maintain remission in people with ulcerative colitis remains unanswered. There were no serious adverse events when probiotics were compared with placebo. However, one study reported similar numbers of serious adverse events in people who had probiotics and those who received 5‐aminosalicylic acid (5‐ASA, an anti‐inflammatory medicine used to treat ulcerative colitis and other conditions. . More information as to what these serious adverse events are, was not provided. </p> <p><b>What was studied in the review?</b> </p> <p>Ulcerative colitis is a chronic disease of the large bowel, which causes inflammation (swelling). Some of the symptoms include tummy pain, diarrhoea and tiredness. Probiotics are living microscopic organisms that are thought to change the growth of bacteria in the bowel and reduce inflammation. </p> <p><b>What are the main results of the review?</b> </p> <p>We searched for randomised controlled trials (RCTs; clinical studies where people are randomly put into one of two or more treatment groups) comparing probiotics with placebo (dummy treatment), probiotics with 5‐ASA and a combination of probiotics and 5‐ASA with 5‐ASA. There were 12 RCTs involving 1473 participants. The trials looked at adult males and females. Only three studies clearly stated that participants were not allowed to take other medication outside of those being compared. </p> <p>1) There was no clear difference in the number of people who had a clinical relapse when probiotics were compared with placebo. </p> <p>2) There was also no clear difference in the number of people who had a clinical relapse when probiotics were compared with 5‐ASA. </p> <p>3) It is uncertain whether probiotics lead to a difference in the number of people who remain in clinical remission compared with placebo because the quality of evidence is very low. </p> <p>4) There was no clear difference in the number of people who remained in clinical remission when probiotics were compared to 5‐ASA. </p> <p>5) When probiotics combined with 5‐ASA was compared to 5‐ASA alone, there was no clear difference in the number of people who remained in clinical remission. </p> <p>6) It is uncertain whether probiotics combined with 5‐ASA lead to a difference in the number of people who have a clinical relapse when compared with 5‐ASA alone. </p> <p>7) No serious adverse events were reported in the trials which compared probiotics with placebo. One study which compared probiotics with 5‐ASA reported similar numbers of serious adverse events with both treatments. Discontinuation of therapy was due to gastrointestinal disorders, such as bloody stools, nausea, diarrhoea and abdominal pain. </p> <p>8) There was not enough information from the studies on how probiotics affect people's quality of life and the need for additional therapy when compared to other treatments. </p> <p><b>Conclusion</b> </p> <p>We are uncertain as to whether probiotics can maintain remission in people with ulcerative colitis. This is because the studies had very few participants and were not conducted using reliable methods. With the evidence presented in these studies, we are unable to make strong conclusions into the effectiveness of probiotics; better designed studies with more participants are needed. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>This review is up‐to‐date as of October 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007443-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007443-sec-0092"></div> <h3 class="title" id="CD007443-sec-0093">Implications for practice</h3> <section id="CD007443-sec-0093"> <p>The effectiveness of probiotics for the maintenance of remission in ulcerative colitis remains unclear. This is due to low‐ to very low‐certainty evidence from poorly conducted studies, which contribute limited amounts of data from a small number of participants. It is uncertain whether probiotics lead to a difference in clinical relapse and the maintenance of remission when compared with placebo (very low‐certainty evidence). Probiotics were compared with 5‐aminosalicylic acid (5‐ASA) (conventional therapy) and there was no clear difference in relapse or maintenance of remission (low‐certainty evidence). There were no serious adverse events in all but one study, which reported similar numbers across the probiotics and 5‐ASA groups, however, no further details were reported. Health‐related quality of life and withdrawal due to adverse events were rarely reported. </p> </section> <h3 class="title" id="CD007443-sec-0094">Implications for research</h3> <section id="CD007443-sec-0094"> <p>This review highlights the need for further well‐designed randomised controlled trials (RCTs) to investigate the efficacy and safety of probiotics for the maintenance of remission in ulcerative colitis. However, we believe it is key to define contextually what the attributes of such trials should be. The majority of the trials compared probiotics with placebo. Future trials comparing probiotics with 5‐ASA would reflect conventional care given to people with ulcerative colitis. Additionally, the length of follow‐up of most studies in this review is much less than in studies assessed by other published reviews on maintenance therapy. Maintenance studies investigating treatment effects for less than 12 months are simply too short to inform clinical practice, where the attrition rates from remission are such that a minimum of one year should be considered for study. We would also strongly suggest that study investigators work to ensure the homogenous nature of their baseline populations from a disease activity standpoint, as we believe it is difficult to consider patients in remission for one month on recruitment the same as those who are 12 years into their remission. The question of sample size is also a major concern, with a minimal use of power calculations using expected effect sizes which were estimated in wide ranging ways and have led to 11 studies with a little over 1000 participants. Given other studies exhibited in other reviews in the field, particularly the high placebo response rate seen (<a href="./references#CD007443-bbs2-0062" title="JairathV , ZouGY , ParkerCP , MacDonaldJK , AlAmeelT , Al Beshir M et al. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database of Systematic Reviews2017, Issue 9. [DOI: 10.1002/14651858.CD011572.pub2]">Jairath 2017</a>), we believe it is likely that such calculations were too optimistic in projected effect sizes, and as such, may have been underpowered to appropriately investigate the agents under study. Considering the ongoing trials, none of these appears to be of the statistical power or length of follow up to address these issues. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007443-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007443-sec-0008"></div> <div class="table" id="CD007443-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Probiotics compared to placebo for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotics compared to placebo for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with ulcerative colitis in remission<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> probiotics<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotics</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse</p> <p>(12 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/>(0.63 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>361<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse was defined as a flare‐up (NCT02361957), CAI ≤ 5 (Yasushi 2015) and persistence of a rectal bleeding score of ≤ 2 on Sutherland DAI score for 3 consecutive days and/or initiation of remission induction therapy for worsening of ulcerative colitis (Matsuoka 2018), respectively </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>554 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>493 per 1000<br/>(399 to 609) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of clinical remission</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/>(0.98 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>141<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of remission is the number of participants who did not relapse. One additional study reported insufficient data for inclusion in the meta‐analysis, therefore, we did not further analyse the results (reported P = 0.643). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>532 per 1000<br/>(308 to 924) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(48 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four studies reported that no serious adverse events occurred.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies reported there were no withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for additional therapy</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean IBD‐Q score with placebo was 3.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.70 points lower<br/>(1.63 lower to 0.23 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scale: IBD‐Q, range 1 ‐7, higher score = better quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CAI</b> : colitis activity index <b>CI:</b> confidence interval; <b>DAI</b> : disease activity index; <b>IBD‐Q</b> : inflammatory bowel disease questionnaire; <b>MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three times: risk of reporting bias and other bias due to imbalance in baseline characteristics, imprecision due to small sample size.<br/><sup>b</sup>Downgraded two times: imprecision due to small sample size from a single study resulting in wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007443-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotics compared to 5‐ASA (mesalazine) for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with ulcerative colitis in remission<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> probiotics<br/><b>Comparison:</b> 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotics</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.84 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>452<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse was based on the presence of all the following: CAI &gt; 6 (or an increase in CAI of at least 3 points with CAI = 4 being exceeded at the same time); endoscopic index &gt; 4; histological signs of acute inflammation (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>) and appearance of ulcerative colitis symptoms or an increase in CAI to more than 4 points (<a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000<br/>(380 to 554) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of clinical remission</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/>(0.90 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of remission is the number of participants who did not relapse.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>848 per 1000<br/>(720 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/>(0.41 to 3.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>327<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events were not reported in detail</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000<br/>(15 to 126) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.46 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>222<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Discontinuation of therapy was due to gastrointestinal disorders, such as bloody stools, nausea, diarrhoea, mucous secretion and abdominal pain </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/>(45 to 221) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for additional therapy</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> <p>(52 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean IBD‐Q score with 5‐ASA was 24.3 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.80 points lower (2.01 lower to 0.41 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scale: IBD‐Q, range 1 ‐32, higher score = better quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>5‐ASA</b> : 5‐aminosalicylic acid; <b>CAI</b> : colitis activity index <b>CI:</b> confidence interval; <b>IBD‐Q</b> : inflammatory bowel disease questionnaire; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two times: risk of attrition bias and other bias due to imbalance in baseline characteristics, imprecision due to sample size not meeting the optimal information size.<br/><sup>b</sup>Downgraded two times: risk of performance and detection bias from an open‐label study and small number of events.<br/><sup>c</sup>Downgraded two times: risk of attrition bias and imprecision due to small sample size.<br/><sup>d</sup>Downgraded three times: risk of attrition bias, imprecision due to small number of events from a single study resulting in wide confidence interval which includes appreciable harm. Serious adverse events were not described in detail.<sup>e</sup>Downgraded three times: risk of attrition bias, imprecision due to small number of events from a single study resulting in wide confidence interval which includes appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007443-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐ASA (mesalazine) for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotic + 5‐ASA (mesalazine) compared to 5‐ASA (mesalazine) for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with ulcerative colitis in remission<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> probiotic + 5‐ASA<br/><b>Comparison:</b> 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic + 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse</p> <p>(12 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.66 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>242<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> l<b>ow<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse was defined as CAI &gt; 4 (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>) and appearance of ulcerative colitis symptoms or an increase in CAI to more than 4 points (<a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1000<br/>(144 to 371) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of clinical remission</p> <p>(24 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/>(0.89 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>122<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of clinical remission is the number of participants who did not relapse.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>840 per 1000<br/>(712 to 992) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> <p>(12 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.29</p> <p>(0.26 to 107.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> l<b>ow<sup>c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two discontinuations in the probiotic arm were due to avascular necrosis of bilateral femoral head and pulmonary thromboembolism. </p> <p>One study (n = 24) reported no events in either arm.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for additional therapy</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>5‐ASA</b> : 5‐aminosalicylic acid; CAI: Colitis activity index <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three times: risk of attrition bias, imprecision due to small number of events and confidence interval which includes appreciable harm.<br/><sup>b</sup>Downgraded two times: risk of performance and detection bias from an open‐label study, imprecision due to small number of events.<br/><sup>c</sup>Downgraded three times: unclear risk of selection bias (lack of information on sequence generation), imprecision due to small number of events in a single study and confidence interval which include appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007443-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007443-sec-0009"></div> <section id="CD007443-sec-0010"> <h3 class="title" id="CD007443-sec-0010">Description of the condition</h3> <p>Ulcerative colitis is a chronic relapsing disease, with the greatest reported incidence in mainland Europe and Scandinavia of 9.2 to 20.3 per 100,000 people (<a href="./references#CD007443-bbs2-0064" title="LoftusEV . Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology2004;126(6):1504-17.">Loftus 2004</a>), totalling approximately 2.2 million sufferers in Europe alone. The peak incidence of the disease occurs between 15 and 25 years of age, and there is another smaller prevalence at ages 55 to 65. The disease is characterised by abdominal pain, bloody diarrhoea and faecal urgency. The diagnosis of ulcerative colitis is based on medical history, signs and symptoms, and any endoscopic or histopathological findings. </p> <p>The disease is caused by diffuse inflammation, which starts at the rectum, spreads proximally, and is limited to the colon. The aetiology behind the disease is unknown, but is likely to be multifactorial; consisting of a genetic predisposition, dysregulation of the mucosal and epithelial barrier and lastly dysbiosis, although whether dysbiosis causes or is a result of the disease remains unclear (<a href="./references#CD007443-bbs2-0078" title="UngaroR , MehandruS , AllenPB , Peyrin-BirouletL , ColombelJF . Ulcerative colitis. Lancet2016;389(10080):1756-70.">Ungaro 2016</a>). The genetic component was further evaluated by <a href="./references#CD007443-bbs2-0054" title="CleynenI . Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet2016;387(10014):156-67.">Cleynen 2016</a> and a strong association between HLA DRB1 and ulcerative colitis was found. The genetic predisposition creates a four‐fold risk for first‐degree relatives. </p> </section> <section id="CD007443-sec-0011"> <h3 class="title" id="CD007443-sec-0011">Description of the intervention</h3> <p>Probiotics are live micro‐organisms, that when consumed, may provide multiple health benefits. They produce their benefits by altering the gut microbiome through either enhancing the activity, volume or both, of the normal flora. <i>Lactobacillus spp,</i> for example, is one of the more popular probiotics and is thought to secrete bacteriocin, blocking the adherence of translocation of harmful bacteria (<a href="./references#CD007443-bbs2-0070" title="PanigrahiP . Probiotics and prebiotics in neonatal necrotizing enterocolitis: new opportunities for translational research. Pathophysiology2014;21(1):35-46.">Panigrahi 2014</a>). </p> <p><i>Lactobacillus rhamnosus GG</i> (<i>L</i> <i>rhamnosus</i>) produced mixed responses in animal models of colitis (<a href="./references#CD007443-bbs2-0056" title="DielemanLA , GoerresMS , ArendsA , SprengersD , TorriceC , HoentjenF , et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut2003;52(3):370-6.">Dieleman 2003</a>; <a href="./references#CD007443-bbs2-0075" title="ShiboletO , KarmeliF , EliakimR , SwennenE , BrigidiP , GionchettiP , et al. Variable response to probiotics in two models of experimental colitis in rats. Inflammatory Bowel Diseases2002;8(6):399-406.">Shibolet 2002</a>), as did <i>Lactobacillus plantarum</i> (<i>L</i> <i>plantarum</i>) 299V (<a href="./references#CD007443-bbs2-0056" title="DielemanLA , GoerresMS , ArendsA , SprengersD , TorriceC , HoentjenF , et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut2003;52(3):370-6.">Dieleman 2003</a>; <a href="./references#CD007443-bbs2-0063" title="KennedyRJ , HoperM , DeodharK , KirkSJ , GardinerKR . Probiotic therapy fails to improve gut permeability in a hapten model of colitis. Scandinavian Journal of Gastroenterology2000;35(12):1266-71.">Kennedy 2000</a>; <a href="./references#CD007443-bbs2-0073" title="SchultzM , VeltkampC , DielemanLA , GrentherWB , WyrickPB , TonkonogySL , et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflammatory Bowel Diseases2002;8(2):71-80.">Schultz 2002</a>). Studies investigating combinations of probiotic species incorporated within De Simone Formulation have demonstrated a partial reduction of colitis in animal models (<a href="./references#CD007443-bbs2-0066" title="MadsenK , CornishA , SoperP , McKaigneyC , JijonH , YachimecC , et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology2001;121(3):580-91.">Madsen 2001</a>; <a href="./references#CD007443-bbs2-0075" title="ShiboletO , KarmeliF , EliakimR , SwennenE , BrigidiP , GionchettiP , et al. Variable response to probiotics in two models of experimental colitis in rats. Inflammatory Bowel Diseases2002;8(6):399-406.">Shibolet 2002</a>). There has been increasing interest in the use of probiotics, as they are considered safe and easily accessible (<a href="./references#CD007443-bbs2-0069" title="OngTG , GordonM , BanksSS , ThomasMR , AkobengAK . Probiotics to prevent infantile colic. Cochrane Database of Systematic Reviews2019, Issue 3. [DOI: 10.1002/14651858.CD012473.pub2]">Ong 2019</a>). It is worth noting that there are a huge number of different preparations available, varying in the specific strains isolated, the use of mixed strains in a single preparation, the form of the preparation and finally the licensing arrangements surrounding the preparations (medicinal versus food products). </p> </section> <section id="CD007443-sec-0012"> <h3 class="title" id="CD007443-sec-0012">How the intervention might work</h3> <p>There is growing evidence looking at the effects of probiotics in the use of inducing remission in ulcerative colitis since a previous Cochrane review (<a href="./references#CD007443-bbs2-0067" title="MallonP , McKayD , KirkS , GardinerK . Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2007, Issue 10. [DOI: 10.1002/14651858.CD005573.pub2]">Mallon 2007</a>). Due to the part that dysbiosis plays in ulcerative colitis, there is potential benefit in trying to restore the endogenous flora. Several observations, both on humans and animal models, emphasised the importance of bacterial flora in inflammatory bowel disease pathogenesis, justifying the current interest in antibiotic and probiotic therapies aimed at the manipulation of enteric flora (<a href="./references#CD007443-bbs2-0016" title="CuiHH , ChenCL , WangJD , YangYJ , CunY , WuJB , et al. Effects of probiotics on intestinal mucosa of patients with ulcerative colitis. World Journal of Gastroenterology2004;10(10):1521-5. ">Cui 2004</a>). The therapeutic efficacy of probiotics has been demonstrated in various models of experimental colitis, including interleukin‐10 deficient mice (<a href="./references#CD007443-bbs2-0065" title="MadsenKL , DoyleJS , JewellLD , TaverniniMM , FedorakRN . Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology1999;116(5):1107-14.">Madsen 1999</a>; <a href="./references#CD007443-bbs2-0073" title="SchultzM , VeltkampC , DielemanLA , GrentherWB , WyrickPB , TonkonogySL , et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflammatory Bowel Diseases2002;8(2):71-80.">Schultz 2002</a>), and acetic acid‐induced colitis in rats (<a href="./references#CD007443-bbs2-0057" title="FabiaR , Ar'RajabA , JohanssonML , WillenR , AnderssonR , MolinG , et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic-induced colitis in the rat. Scandinavian Journal of Gastroenterology1993;28(2):155-62.">Fabia 1993</a>). </p> </section> <section id="CD007443-sec-0013"> <h3 class="title" id="CD007443-sec-0013">Why it is important to do this review</h3> <p>In the UK, National Institute for Health and Care Excellence (NICE) and USA guidelines state that first‐line therapy for maintenance of remission in ulcerative colitis is 5‐aminosalicylic acid (5‐ASA) (<a href="./references#CD007443-bbs2-0068" title="National Institute for Health and Care Excellence. Ulcerative Colitis Mangagement NG130. https://www.nice.org.uk/guidance/ng1302019.">NICE 2019</a>). 5‐ASA works by binding to PPAR‐ỿ and reducing cytokine production. Some of the adverse effects associated with 5‐ASA include headache, rash, nausea (common), pancreatitis (uncommon), and agranulocytosis (rare). Due to these side effects, some people are unable to tolerate the drug. If 5‐ASA fails to work then other therapies to maintain remission include immune suppressants, such as anti‐tumour necrosis factor (TNF) monoclonals, vedolizumab and tofacitinib may be used. These drugs work by blocking leukocyte recruitment at the molecular and vascular level (<a href="./references#CD007443-bbs2-0058" title="FiorinoG . The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. Therapeutic Advances in Gastroenerology2016;9(4):503-12.">Fiorino 2016</a>), some of the side effects include headache, dizziness and arthralgia. </p> <p>The relapsing and remitting nature of the disease means that people can be in and out of hospital, experimenting with different drug regimes. The treatment costs Europe between GBP 11 to 26 billion pounds annually, with per patient costs approximately GBP 8011 to 9306 (<a href="./references#CD007443-bbs2-0055" title="CohenRD . Systematic review: the costs of ulcerative colitis in Western countries. Alimentary Pharmaology and Therapeutics2010;31(7):693-707.">Cohen 2010</a>). If an alternative, cheaper treatment can be found for ulcerative colitis, then it would greatly benefit not only a budget stricken National Health Service (NHS), but also improve patients' quality of life. Whilst some studies have suggested that probiotics may be useful for maintenance of remission in mild to moderate ulcerative colitis (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>), others have failed to show any benefit (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0035" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>). In this review we investigate the available evidence on the use of probiotics for the maintenance of remission in ulcerative colitis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007443-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007443-sec-0014"></div> <p>The primary objective was to determine the efficacy of probiotics compared to placebo, no treatment, or any other intervention for the maintenance of remission in people with ulcerative colitis. The secondary objective was to assess the occurrence of adverse events associated with the use of probiotics. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007443-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007443-sec-0015"></div> <section id="CD007443-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007443-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs), with a minimum duration of three months, for inclusion in the review. </p> </section> <section id="CD007443-sec-0018"> <h4 class="title">Types of participants</h4> <p>People of any age with ulcerative colitis in remission, defined as clinical, endoscopic, histological or radiological relapse by study authors. </p> </section> <section id="CD007443-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Probiotics administered in any form (drink, powder, capsule), orally as a single species, or as a cocktail of multiple species compared to no treatment, placebo or any other intervention. </p> </section> <section id="CD007443-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD007443-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007443-list-0001"> <li> <p>Relapse (clinical, endoscopic, histopathological or radiological), as defined by the authors of the primary studies. </p> </li> </ul> </p> <p>Where studies reported on the number of participants who did not experience a relapse, i.e. those who remained in remission, this was noted under 'maintenance of clinical remission'. </p> </section> <section id="CD007443-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007443-list-0002"> <li> <p>Serious adverse events</p> </li> <li> <p>Withdrawal due to adverse events</p> </li> <li> <p>Need for additional therapy</p> </li> <li> <p>Health‐related quality of life, as measured by a validated quality of life tool</p> </li> </ul> </p> </section> </section> </section> <section id="CD007443-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007443-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive and systematic search to identify RCTs from inception to 31 October 2019 using the following databases. </p> <p> <ul id="CD007443-list-0003"> <li> <p>Cochrane Inflammatory Bowel Disease (IBD) Specialized Trials Register</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>MEDLINE</p> </li> <li> <p>Embase</p> </li> <li> <p>CINAHL</p> </li> </ul> </p> <p>We did not place any restrictions on publication dates (after 1966) or language. See <a href="./appendices#CD007443-sec-0098">Appendix 1</a> for the detailed search strategies. </p> </section> <section id="CD007443-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We inspected the reference lists of all identified studies for more trials. We also contacted leaders in the field and manufacturers of probiotics to identify potentially relevant studies. We also searched ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) for ongoing trials (<a href="./appendices#CD007443-sec-0098">Appendix 1</a>). </p> </section> </section> <section id="CD007443-sec-0026"> <h3 class="title" id="CD007443-sec-0026">Data collection and analysis</h3> <p>We conducted data collection and analysis according to methods stipulated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007443-bbs2-0061" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <section id="CD007443-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We undertook study selection in Covidence. Using the above search strategy, two review authors (LK, ZIE) identified titles that appeared to be potentially relevant. These were independently screened and in circumstances of disagreement, a third review author (AA) was involved to reach consensus. </p> <p>There is some evidence that data from abstract publications can be inconsistent with data from published articles (<a href="./references#CD007443-bbs2-0071" title="PitkinRM , BranaganMA , BurmeisterLF . Accuracy of data in abstracts of published research articles. JAMA1999;281:1110-1.">Pitkin 1999</a>), therefore we considered abstract publications, but only if sufficient data were presented to judge inclusion criteria fully and reports of the primary and secondary outcomes were given. If these were not available, we contacted authors directly, and if data were not provided, we excluded such studies. </p> <p>The review authors, after reading the full texts, independently assessed the eligibility of all trials identified using ad hoc eligibility, based on the inclusion criteria above. Disagreement among review authors was again discussed, and agreement was reached by consensus after involvement of a third review author. We contacted authors of multiple publications, which appeared to report on the same study, for clarification. A flow chart was included (<a href="#CD007443-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007443-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007443-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007443-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We developed a data extraction form and used it to extract information on relevant features and results of included studies. Two review authors (LK, ZIE) independently extracted and recorded data on a predefined checklist. Again, when disagreements occurred, a third review author (AA) was involved and consensus was reached. Extracted data included the following items. </p> <p> <ul id="CD007443-list-0004"> <li> <p>Characteristics of participants: age, sex, disease distribution, disease duration, disease activity index </p> </li> <li> <p>Total number of participants originally assigned to each intervention group</p> </li> <li> <p>Intervention: type and dose of probiotic(s)</p> </li> <li> <p>Control: no intervention, placebo or other interventions</p> </li> <li> <p>Concurrent medications</p> </li> <li> <p>Outcomes: time of assessment, length of follow‐up, type of symptom score used or ulcerative colitis activity index, definition of remission and relapse, relapse rates, time to relapse, quality of life assessment, and adverse events </p> </li> </ul> </p> <p>We resolved inconsistencies in data extraction, and transferred the information above into the <a href="./references#CD007443-sec-0114" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD007443-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LK, ZIE) independently assessed risk of bias using the Cochrane 'Risk of bias' tool (<a href="./references#CD007443-bbs2-0061" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We assessed the following domains. </p> <p> <ul id="CD007443-list-0005"> <li> <p>Selection bias</p> <ul id="CD007443-list-0006"> <li> <p>Sequence generation (i.e. was the allocation sequence adequately generated?)</p> </li> <li> <p>Allocation sequence concealment (i.e. was allocation adequately concealed?)</p> </li> </ul> </li> <li> <p>Performance bias (i.e. was knowledge of the allocated intervention adequately prevented during the study towards the participants?) </p> </li> <li> <p>Detection bias (i.e. were outcome assessors blinded adequately?)</p> </li> <li> <p>Attrition bias (were attritions and exclusions adequately reported?)</p> </li> <li> <p>Reporting bias: selective outcome reporting (i.e. are reports of the study free of suggestion of selective outcome reporting?) </p> </li> <li> <p>Other potential sources of bias (i.e. was the study apparently free of other problems that could put it at a high risk of bias?) </p> </li> </ul> </p> <p>We considered subjective outcomes separately in our assessment of blinding and incompleteness of data. We judged studies to be at 'high', 'low' or 'unclear' risk of bias for each domain assessed. We judged the risk of bias across studies as follows. </p> <p> <ul id="CD007443-list-0007"> <li> <p>Low risk of bias (plausible bias unlikely to seriously alter the results) if all domains are at low risk of bias. </p> </li> <li> <p>Unclear risk of bias (plausible bias that raises some doubt about the results) if one or more domains are at unclear risk of bias. </p> </li> <li> <p>High risk of bias (plausible bias that seriously weakens confidence in the results) if one or more domains are at high risk of bias. </p> </li> </ul> </p> <p>Disagreements were resolved by consensus. We contacted study authors when insufficient information was provided to determine the risk of bias. Where we obtained information supporting our judgement on risk of bias through correspondence with study authors, we indicated this in the 'Risk of bias' table. </p> </section> <section id="CD007443-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>The measure of treatment effect for dichotomous outcomes was risk ratios (RRs). Where continuous outcomes reported with the same scale, we used mean differences (MDs). </p> </section> <section id="CD007443-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant. Where studies assessed more than two interventions which are relevant to the review, we made multiple pair wise comparisons and analysed just the groups of interest. We did not include the same group of participants twice in the same meta‐analysis. We were alert to the unit of analysis issues relating to outcome reporting at different follow‐up times and only reported outcomes at final follow‐up. </p> </section> <section id="CD007443-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to request missing data. Where authors reported both intention‐to‐treat (ITT) and per protocol analysis, we preferred the former. However, where ITT analysis was not conducted or reported in the studies, we regarded withdrawals as failures. We undertook sensitivity analyses to exclude studies with missing data. We did not impute missing standard deviations (SDs). However, we noted any instances where data were extracted from graphs. </p> </section> <section id="CD007443-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity among trial results by inspection of graphical presentations and by calculating the Chi<sup>2</sup> test of heterogeneity; we regarded P = 0.10 as statistically significant. We used the I<sup>2</sup> statistic to quantity the effect of heterogeneity (<a href="./references#CD007443-bbs2-0060" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> <p>We based our interpretation of the I<sup>2</sup> statistic results on those suggested by <a href="./references#CD007443-bbs2-0061" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a> (Section 9.5.2): </p> <p> <ul id="CD007443-list-0008"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%; may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD007443-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We avoided different reporting biases by conducting an extensive literature search. It was not necessary to generate a funnel plot to investigate publication bias, as there were an insufficient number of studies contributing to the analysis. </p> </section> <section id="CD007443-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We pooled studies with the same population, intervention, comparator and outcomes; we did not pool studies which were clinically heterogenous. We used Review Manager 5 for data analysis (<a href="./references#CD007443-bbs2-0072" title="The Cochrane CollaborationThe Nordic Centre. Copenhagen: The Cochrane Collaboration, 13th June 2014.Available at https://community.cochrane.org/help/tools-and-software/revman-5.">Review Manager 2014</a>). For dichotomous variables, we calculated RRs and 95% confidence intervals (CIs) based on a random‐effects model. For continuous variables, we calculated the MD and 95% CIs when continuous outcomes were measured using the same units. We used the fixed‐effect model, as I<sup>2</sup> = 0. We had planned to use the random‐effects model if I<sup>2</sup> had been &gt; 0. </p> </section> <section id="CD007443-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Had we included a sufficient number of studies, we would have carried out subgroup analyses based on: </p> <p> <ul id="CD007443-list-0009"> <li> <p>age (below 18 years and above 18 years); and</p> </li> <li> <p>species of probiotic.</p> </li> </ul> </p> </section> <section id="CD007443-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out the following sensitivity analyses, apart from the exclusion of studies at high risk of bias; this was not possible due to the paucity of data. </p> <p> <ul id="CD007443-list-0010"> <li> <p>Only including participants whose outcome is known (i.e. number of participants who completed the study used as denominator) </p> </li> <li> <p>Study quality (removing those at highest risk of bias)</p> </li> <li> <p>Random‐effects versus fixed‐effect models</p> </li> </ul> </p> </section> <section id="CD007443-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the certainty of evidence related to all outcomes listed in the <a href="#CD007443-sec-0020">Types of outcome measures</a> (<a href="./references#CD007443-bbs2-0074" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>). The four levels of evidence certainty are 'high', 'moderate', 'low' or 'very low'. Certainty may be downgraded due to study limitations (risk of bias), imprecision, inconsistency, indirectness or publication bias. We derived the optimal information size for the primary outcomes from the included studies. </p> <p>Two review authors (MG, ZIE) independently produced 'Summary of findings' tables using the GRADEpro GDT software for our main comparisons (<a href="./references#CD007443-bbs2-0059" title="McMaster UniversityGRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2015 (developed by Evidence Prime, Inc.).Available from gradepro.org.">GRADEpro GDT 2015</a>). We presented the results for clinical relapse, maintenance of clinical remission, health‐related quality of life, need for additional therapy, serious adverse events, and withdrawal due to serious adverse events. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007443-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007443-sec-0039"></div> <section id="CD007443-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD007443-sec-0041"> <h4 class="title">Results of the search</h4> <p>The literature search returned 1473 unique records after duplicates were removed; we also identified an additional study from another source. After screening 1474 titles and abstracts, we found 52 studies that met our inclusion criteria. We obtained and screened the full‐text copies of these 52 studies. We included 12 studies and excluded 30 studies with reasons. We contacted authors of eight studies for additional information (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>); we received responses from three authors (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>). We identified four ongoing studies and six studies are awaiting classification (<a href="./references#CD007443-sec-0117" title="">Characteristics of ongoing studies</a>; <a href="./references#CD007443-sec-0116" title="">Characteristics of studies awaiting classification</a>). The results of the search are presented in the PRISMA flow diagram <a href="#CD007443-fig-0001">Figure 1</a>. Full details of the included and excluded studies are available in the <a href="./references#CD007443-sec-0114" title="">Characteristics of included studies</a> and <a href="./references#CD007443-sec-0115" title="">Characteristics of excluded studies</a> tables and are summarised below. </p> </section> <section id="CD007443-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD007443-sec-0043"> <h5 class="title">Study design and setting</h5> <p>We included 12 studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). These studies were either single centre (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>), or multicentre (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>) parallel group RCTs. The studies were conducted in hospitals in Italy (<a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>), Iran (<a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>), Ireland (<a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>), Japan (<a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>), the Netherlands (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>), Romania (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>), the UK (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>); multiple centres in Denmark (<a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>) and Japan (<a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>); multiple centres across Germany, the Czech Republic, Austria (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>) and Germany, the Czech Republic, Austria, Estonia, Latvia, Lithuania, Slovak Republic, Sweden, Switzerland and the UK (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>). In two studies (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>), where the setting was not explicitly stated, we have assumed this to be the authors' affiliation. </p> </section> <section id="CD007443-sec-0044"> <h5 class="title">Participants</h5> <p>In five studies reporting mean age, the average age of participants was between 32 years in <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a> and 51 years in <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>). In five studies reporting on age range, included participants were between 18 in <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a> and 88 years in <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>. Only one study (<a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>), which based on its inclusion criteria may have included paediatric patients (&gt; 13 years). This study had an overall mean age of 43.9 +/‐ 14.8 years, therefore, it is unclear whether children were recruited. Ten out of 11 studies randomised 25 (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>) to 327 (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>) participants. <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a> included 36 participants, some (number not stated) of which received interventions that are outside the scope of this review. The studies included male and female participants with ulcerative colitis who may or may not have been receiving medication at the time of recruitment, except for <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a> who did not report on age and sex, making it unclear whether the study was conducted on adult and/or paediatric female and/or male patients. In 10 studies, participants had the following forms of ulcerative colitis: pancolitis, left‐sided, total colitis, proctitis, proctosigmoiditis, total colitis, subtotal colitis, distal, left colon. However, three studies did not provide any information on the extent of disease (<a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>). The length of time participants had been in remission at the point of study entry was not stated in six studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>), and unclear in one study (<a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>). Three studies reported at recruitment, that participants had been in remission between one month in <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a> and <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a> and 12 years in <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>. </p> </section> <section id="CD007443-sec-0045"> <h5 class="title">Intervention</h5> <p>All the included studies had two trial arms, except three studies (<a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>), which had three trial arms. <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a> had three trial arms, however, one arm was excluded for assessing an intervention (prebiotic) that is not relevant to the review. The studies investigated the following comparisons. </p> <p> <ul id="CD007443-list-0011"> <li> <p>Probiotics versus placebo (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>) </p> </li> <li> <p>Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine) (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>) </p> </li> <li> <p>Probiotics plus 5‐ASA versus 5‐ASA (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>) </p> </li> <li> <p>Probiotics plus 5‐ASA versus 5‐ASA plus placebo (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>) </p> </li> <li> <p>Probiotics versus probiotics versus placebo (<a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>) </p> </li> <li> <p>Probiotics versus probiotics plus 5‐ASA versus 5‐ASA (<a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>) </p> </li> </ul> </p> <p>In seven studies (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>), the probiotics contained single bacterial strains and probiotics in five studies contained multiple strains (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>). These single bacterial strains include <i>Bifidobacterium longum</i> (<i>B longum</i>) W11 (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>), <i>Echerichia coli</i> (<i>E coli</i>) Nissle 1917 (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>), <i>Lactobacillus salivarius</i> (<i>L salivarius</i>) UCC118 (<a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>), <i>Bifidobacterium infantis</i> (<i>B</i> <i>infantis</i>) 35624 (<a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>), <i>Lactobacillus</i> <i>casei</i> (<i>L casei</i>) strain ATCC PTA‐3945 (<a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>), and <i>Lactobacillus GG</i> 18 X 10<sup>9</sup> (<a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). </p> <p>In studies with multiple strain probiotics, the following combinations were studied.</p> <p> <ul id="CD007443-list-0012"> <li> <p><i>Lactobacillus rhamnosus (L rhamnosus) NCIMB 30174, Lactobacillus plantarum (L plantarum) NCIMB 30173, Lactobacillus acidophilus (L acidophilus) NCIMB 30175 and Enterococcus faecium (E faecium) NCIMB 30176</i> (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>). </p> </li> <li> <p><i>Bifidobacterium bifidum (B bifidum) W23, Bifidobacterium lactis (B lactis) W51, Bifidobacterium lactis (B lactis) W52, L acidophilus W22, L casei W56, Lactobacillus paracasei (L paracasei) W20, Lactobacillus plantarum (L plantarum) W62, L salivarius W24 and Lactococcus lactis (L lactis) W19</i> (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>). </p> </li> <li> <p><i>Bifidobacterium</i> <i>breve</i> (<i>B breve) and L acidophilus</i> (<a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>). </p> </li> <li> <p><i>L acidophilus</i> strain La‐5 + <i>Bifidobacterium animalis (B animalis) subsp</i> . <i>lactis</i> strain BB‐12 (<a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>). </p> </li> <li> <p><i>Streptococcus faecalis</i> (<i>S</i> <i>faecalis)</i> T‐110 (lactomin) + <i>Clostridium butyricum</i> TO‐A + <i>Bacillus mesentericus</i> (<a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>). </p> </li> </ul> </p> <p>Interventions were administered daily for four weeks in <a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a> to 52 weeks (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). Concomittant treatments were not allowed in three studies (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>), and in five studies it was not explicitly stated whether concomitant treatments were used or not. In four studies different concomitant treatments were used, such as 5‐aminosalycilic preparation, low‐dose azathioprine (1 mg/kg) and prednisolone &lt; 4 mg/day (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>), 2.4 g per day of mesalazine (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>), aminosalicylate (<a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>), unrestricted mesalazine and salazosulfapyridine plus topical antibiotics were not restricted (<a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>). </p> </section> <section id="CD007443-sec-0046"> <h5 class="title">Outcomes</h5> <p>The studies reported data on all outcomes of interest except 'need for withdrawal of therapy'. We summarised outcome data in <a href="#CD007443-tbl-0004">Table 1</a>. </p> <div class="table" id="CD007443-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome data table</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of relapses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition of relapse</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Maintenance of remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of life</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Withdrawal due to adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 versus 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 +/‐ 2.8 versus 8.0 +/‐ 2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13 versus 1/12;</p> <p>0/13 versus 2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse was defined as a flare‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 +/‐ 0.7 versus 4.2 +/‐ 1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30% versus 28%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77% versus 90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/50 versus 6/53;</p> <p>18/60 versus 13/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAI &gt; 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/50 versus 1/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/110 versus 38/112; 92/162 versus 91/165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The presence of all of the following: CAI &gt; 6 (or an increase in CAI of at least 3 points with CAI = 4 being exceeded at the same time); endoscopic index &gt; 4; histological signs of acute inflammation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3 +/‐ 5.2 versus 25.1 +/‐ 3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/162 versus 6/165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/110 versus11/112; 63/162 versus 64/165</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/97 versus 19/95</p> <p>55/98 versus 58/97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The persistence of a rectal bleeding score of ≥ 2 on Sutherland DAI score for 3 consecutive days and/or initiation of remission induction therapy for worsening of UC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported P = 0.643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/97 versus 2/95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as &lt; 3 bowel movements per day (without frank/gross blood) out of 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/14 versus 4/15;</p> <p>4/14 versus 7/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An increase in bowel frequency with blood for at least 1 week. A colonoscopy was performed and biopsies were taken to confirm relapse </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/20 versus 11/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCCAI score &gt; 4 and/or endoscopic changes grade 2–3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/20 versus 1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 versus 0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 versus 0/12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/23 versus 10/23;</p> <p>14/30 versus 17/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAI ≤ 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/23 versus 13/23</p> <p>16/30 versus 13/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/23 versus 0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/12 versus 2/10 versus 4/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined by clinical and endoscopic features</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/12 versus 0/10 versus 0/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/65 (Probiotic) versus 12/60 (Mesalazine) versus 10/62 (Probiotic+Mesalazine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The appearance of UC symptoms or an increase in CAI to more than 4 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/65 versus 48/60 versus 52/62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/65 versus 0/60 versus 0/62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Serious adverse events which occurred were reportedly not related to the intervention (avascular necrosis of bilateral femoral head and pulmonary thromboembolism) </p> <p>CAI: colitis activity index; DAI: disease activity index; NR: not reported; SCCAI: simple clinical colitis activity index UC: ulcerative colitis </p> </div> </div> <p> <ul id="CD007443-list-0013"> <li> <p>Relapse was reported in all studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). Clinical relapse was reported in six studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). In three studies, endoscopic and clinical relapse were not separated out (<a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>). </p> </li> <li> <p>Maintenance of remission (the number of participants who did not have a relapse) was reported in five studies (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). Maintenance of clinical remission was reported in three studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). </p> </li> <li> <p>Health related quality of life was reported in three studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>). </p> </li> <li> <p>Serious adverse events were reported in seven studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>), although no full description was provided. Therefore, we were unable to ascertain the severity of the adverse events. </p> </li> <li> <p>Withdrawal due to adverse events was reported in five studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>). </p> </li> </ul> </p> </section> <section id="CD007443-sec-0047"> <h5 class="title">Funding and declaration of interest</h5> <p>The studies were government funded (<a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>), funded by manufacturing companies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>), part funded by industry and a charity (<a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>), and part funded by government and industry (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>). The funding source was not reported in six studies (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). </p> <p>Conflict of interest was not fully reported in any of the studies except <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>, in which the authors reported that they had none. Three studies reported that one author had no conflict of interest (<a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>), and two authors were funded by manufacturing companies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>). Two studies reported that authors were employed by a manufacturing company (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>). Conflicts of interest were not reported in five studies (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). </p> </section> </section> <section id="CD007443-sec-0048"> <h4 class="title">Excluded studies</h4> <p>Thirty studies failed to meet the inclusion criteria and we excluded them for the following reasons. </p> <p> <ul id="CD007443-list-0014"> <li> <p>Wrong study design: review (<a href="./references#CD007443-bbs2-0017" title="DoVT , BairdBG , KocklerDR . Probiotics for maintaining remission of ulcerative colitis in adults. Annals of Pharmacotherapy2010;44(3):565-71. ">Do 2010</a>), commentary piece (<a href="./references#CD007443-bbs2-0018" title="FaubionWA , SandbornWJ . Probiotic therapy with E. Coli for ulcerative colitis: take the good with the bad. Gastroenterology2000;118(3):630-1. ">Faubion 2000</a>; <a href="./references#CD007443-bbs2-0019" title="FolwacznyC . Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment. Zeitschfrift de Gastroenterologie2000;38(6):547-50. ">Folwaczny 2000</a>), not a RCT (<a href="./references#CD007443-bbs2-0021" title="HenkerJ , MüllerS , LaassMW , SchreinerA , SchulzeJ . Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Zeitschrift fur Gastroenterologie2008;46(9):874-5. ">Henker 2008</a>; <a href="./references#CD007443-bbs2-0041" title="VenturiA , GionchettiP , RizzelloF , JohanssonR , ZucconiE , BrigidiP , et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics1999;13(8):1103-8. ">Venturi 1999</a>). </p> </li> <li> <p>Wrong population: participants were not in remission at study entry (<a href="./references#CD007443-bbs2-0020" title="FujimoriS , GudisK , MitsuiK , SeoT , YonezawaM , TanakaS , et al. Randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition2009;25(5):520-5. ">Fujimori 2009</a>; <a href="./references#CD007443-bbs2-0022" title="IRCT20120415009475N5. Evaluation of the effects of Saccharomyces Boulardii on pain and quality of life in children with Inflammatory Bowel Disease (IBD) [Evaluation of the effects of lyophilized Saccharomyces Boulardii capsules on quality of life and clinical outcomes in children with inflammatory bowel disease (IBD)]. www.irct.ir/trial/32179 (registration date 10 October 2018). [IRCT: https://www.irct.ir/trial/32179]">IRCT20120415009475N5</a>; <a href="./references#CD007443-bbs2-0025" title="LiK , ZhangCF , XiaYH , Li ZJ , HanY . Efficacy of probiotics on ulcerative colitis and its mechanism. Zhonghua Weichang Waike Zazhi2013;16(4):336-9. ">Li 2013</a>; <a href="./references#CD007443-bbs2-0026" title="LiuP , SunL , ZhangZH , ZhangP , ZhangJ . Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology2014;22(22):3344-8. ">Liu 2014</a>; <a href="./references#CD007443-bbs2-0027" title="MieleE , PascarellaF , GiannettiE , QuagliettaL , BaldassanoRN , StaianoA . Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology2009;104(2):437-43. ">Miele 2009</a>; <a href="./references#CD007443-bbs2-0032" title="NCT01772615. Treatment of ulcerative colitis with ciprofloxacin and E. Coli Nissle. clinicaltrials/gov/show/NCT01772615 First posted 21 january 2013. ">NCT01772615</a>; <a href="./references#CD007443-bbs2-0035" title="RembackenBJ , SnellingAM , HawkeyPM , ChalmersDM , AxonAT . Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet1999;354(9179):635-9. ">Rembacken 1999</a>; <a href="./references#CD007443-bbs2-0037" title="Sanchez-MoralesA , Perez-AyalaMF , Cruz-MartinezM , Arenas-OsunaJ , Ramirez-MendozaP , CenicerosRA , et al. Efectividad de probioticos sobre sintomas, histologia, y tolerancia alimentaria en colitis ulcerativa. Revista Medica del Instituto Mexicano del Seguro Social2019;57(1):9-14. ">Sanchez‐Morales 2019</a>; <a href="./references#CD007443-bbs2-0042" title="ZhangJ . Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology2018;26(6):373-7. ">Zhang 2018a</a>), a mixed population of active and inactive ulcerative colitis (<a href="./references#CD007443-bbs2-0024" title="IshikawaH , MatsumotoS , OhashiY , ImoakaA , SetoyamaH , UmesakiY , et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: A randomized controlled study. Digestion2011;84(2):128-33. ">Ishikawa 2011</a>), mixed population of ulcerative colitis and Crohn's disease (<a href="./references#CD007443-bbs2-0014" title="BalliniA , SantacroceL , CantoreS , BottalicoL , DipalmaG , TopeS , et al. Probiotics efficacy on oxidative stress values in inflammatory bowel disease: a randomized double-blinded placebo-controlled pilot study. Endocrine, Metabolic &amp; Immune Disorders - Drug Targets2019;19(3):1-8. ">Ballini 2019</a>; <a href="./references#CD007443-bbs2-0038" title="ShadnoushM , HosseiniRS , MehrabiY , DelpishehA , AlipoorE , FaghfooriZ , et al. Probiotic yogurt affects pro- and anti-inflammatory factors in patients with inflammatory bowel disease. Iranian Journal of Pharamceutical Research2013;12(4):929-36. ">Shadnoush 2013</a>), participants had active ulcerative colitis (<a href="./references#CD007443-bbs2-0031" title="NCT00951548. Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis. clinicaltrials.gov/show/NCT00951548 First posted 4 August 2009. ">NCT00951548</a>; <a href="./references#CD007443-bbs2-0033" title="PalumboVD , RomeoM , Marino GammazzaA , CariniF , DamianiP , Damiano G et al. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia2016;160(3):372-7. ">Palumbo 2016</a>; <a href="./references#CD007443-bbs2-0039" title="SolovyevaO . Probiotics can extend remission of ulcerative colitis. Journal of Crohn's and Colitis2014;8:221. ">Solovyeva 2014</a>; <a href="./references#CD007443-bbs2-0040" title="TursiA , BrandimarteG , PapaA , GiglioA , EliseiW , GiorgettiGM , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology2010;105(10):2218-27. ">Tursi 2010</a>), microscopic colitis (<a href="./references#CD007443-bbs2-0036" title="RohatgiS , AhujaV , MakhariaGK , RaiT , DasP , DattaguptaS , et al. VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial. BMJ Open Gastroenteroilogy2015;2(1):e000018. ">Rohatgi 2015</a>). </p> </li> <li> <p>Wrong intervention (<a href="./references#CD007443-bbs2-0015" title="BambaT , KanauchiO , AndohA , FujiyamaY . A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. Journal of Gastroenterology and Hepatology2002;17(8):818-24. ">Bamba 2002</a>). </p> </li> <li> <p>Short duration of follow‐up (<a href="./references#CD007443-bbs2-0013" title="AhmedJ , ReddyBS , MolbakL , LeserTD , MacfieJ . Impact of probiotic on colonic microflora in patients with colitis: A prospective double blind randomised crossover study. International Journal of Surgery2013;11(10):1131-6. ">Ahmed 2013</a>; <a href="./references#CD007443-bbs2-0016" title="CuiHH , ChenCL , WangJD , YangYJ , CunY , WuJB , et al. Effects of probiotics on intestinal mucosa of patients with ulcerative colitis. World Journal of Gastroenterology2004;10(10):1521-5. ">Cui 2004</a>). </p> </li> <li> <p>Insufficient information on study details and no response when authors were contacted (<a href="./references#CD007443-bbs2-0023" title="IshikawaH , AkedoI , UmesakiY , TanakaR , ImaokaA , OtaniT . Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. Journal of the American College of Nutrition2002;22(1):56-63. ">Ishikawa 2002</a>; <a href="./references#CD007443-bbs2-0028" title="NCT00268164. Lactobacilus acidophilus and Bifidobaceterium animalis subsp. Lactis maintenance treatment in ulcerative colitis. clinicaltrials.gov/show/NCT00268164 First received 22 December 2005. ">NCT00268164</a>; <a href="./references#CD007443-bbs2-0029" title="NCT00374725. Treatment of Ulcerative Colitis With a Combination of Lactobacillus Rhamnosus and Lactobacillus Acidophilus. clinicaltrials.gov/show/NCT00374725 First posted 11 September 2006. ">NCT00374725</a>; <a href="./references#CD007443-bbs2-0030" title="NCT00803829. Sunbiotic treatment of ulcerative colitis patients. clinialtrials.gov/show/NCT00803829 First posted 8 December 2008. ">NCT00803829</a>; <a href="./references#CD007443-bbs2-0034" title="PelechT , FricP , FixaB , KomarkovaO . Comparison of mutaflor and mesalazine in the maintenance treatment of inactive ulcerative colitis. Prakticky Lekar1998;78(10):556-8. ">Pelech 1998</a>). </p> </li> </ul> </p> </section> </section> <section id="CD007443-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>The studies were either at high or unclear risk of bias. The risk of bias for the studies is summarised in <a href="#CD007443-fig-0002">Figure 2</a> and <a href="#CD007443-fig-0003">Figure 3</a>. Further details are available in the <a href="./references#CD007443-sec-0114" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD007443-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007443-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD007443-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007443-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD007443-sec-0050"> <h4 class="title">Allocation</h4> <section id="CD007443-sec-0051"> <h5 class="title">Random sequence generation</h5> <p>In all the included studies, allocation of participants to intervention or placebo was described as random. The method of randomisation was adequately described in six studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>), and not described in six studies (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). We contacted the authors of these six studies to clarify the method of randomisation, but did not receive further information. We rated these studies as unclear risk of bias for sequence generation. </p> </section> <section id="CD007443-sec-0052"> <h5 class="title">Allocation concealment</h5> <p>We rated allocation concealment as unclear for all except two studies (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>). We contacted the authors to clarify allocation concealment, but did not receive a response. The interventions in <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a> were delivered in identical containers from the central pharmacy, therefore we rated this study as low risk of bias. </p> </section> </section> <section id="CD007443-sec-0053"> <h4 class="title">Blinding</h4> <p>Nine of the studies were described as double‐blinded (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>), and we rated them at low risk of performance bias. However, only three of these studies provided information (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>), which suggests that blinding was maintained until after outcome assessment. We rated all three studies at low risk of detection bias, and the remaining as unclear. <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a> and <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a> were open‐label studies and we rated them at high risk of bias. There was insufficient information in <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a> to make a decision, therefore it we rated it at unclear risk of performance and detection bias. </p> </section> <section id="CD007443-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>Ten studies were at low risk of bias for reporting data for all participants (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>), conducting full ITT analysis (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>), a combination of low attrition rates and partial ITT analysis (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>), and two studies had attrition rates of &gt; 20% (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>), but balanced between both groups. Two studies were at unclear risk of bias (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>). </p> </section> <section id="CD007443-sec-0055"> <h4 class="title">Selective reporting</h4> <p>Trial registrations were available for only three studies (<a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>). </p> <p>Of the seven trials which we rated at low risk of reporting bias, two reported all outcomes which were prespecified in the trial registration (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>), and five had no trial registration, but reported all expected outcomes (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). We rated three studies at high risk of bias for reporting more outcomes than specified in the protocol (<a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>), failing to report adverse events (<a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>), and results of biochemical tests (<a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>), <a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a> and <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a> failed to provide sufficient information for a judgement to be made (unclear). </p> </section> <section id="CD007443-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>We rated six studies at low risk of bias for not having other apparent biases (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). We rated three studies at high risk of bias due to an imbalance in baseline characteristics (<a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>), a posthoc decision to discontinue the trial (<a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>), and for being funded by the manufacturer of the probiotic product studied with no justification of the limits or level of involvement (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>) </p> </section> </section> <section id="CD007443-sec-0057"> <h3 class="title" id="CD007443-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD007443-tbl-0001"><b>Summary of findings 1</b> Probiotics compared to placebo for maintenance of remission in ulcerative colitis</a>; <a href="./full#CD007443-tbl-0002"><b>Summary of findings 2</b> Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for maintenance of remission in ulcerative colitis</a>; <a href="./full#CD007443-tbl-0003"><b>Summary of findings 3</b> Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐ASA (mesalazine) for maintenance of remission in ulcerative colitis</a> </p> <section id="CD007443-sec-0058"> <h4 class="title">Probiotics versus placebo</h4> <p>Seven studies compared probiotics with placebo (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>; <a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>; <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>; <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a>). See <a href="./full#CD007443-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD007443-sec-0059"> <h5 class="title">Primary outcome</h5> <section id="CD007443-sec-0060"> <h6 class="title">Clinical relapse</h6> <p>We found very low‐certainty evidence that, on average, there was no clear difference in the incidence of clinical relapse between probiotics and placebo (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.63 to 1.18; 4 studies, 361 participants; very low‐certainty evidence; <a href="./references#CD007443-fig-0006" title="">Analysis 1.1</a>, <a href="#CD007443-fig-0004">Figure 4</a>). We downgraded the evidence three times for high risk of reporting and other bias due to imbalance in baseline characteristics, and imprecision due to small sample size. </p> <div class="figure" id="CD007443-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.1 Clinical relapse." data-id="CD007443-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.1 Clinical relapse.</p> </div> </div> </div> <p>Two other studies also reported on relapse (<a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>). In these studies, relapse data appear to have included a mix of endoscopic and clinical relapse. <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a> defines relapse as: an increase in bowel frequency with blood for at least one week and a colonoscopy and biopsies to confirm relapse. <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a> defines relapse as: simple clinical colitis activity index (SCCAI) score &gt; 4 and/or endoscopic changes grade 2 to 3. Due to concerns about clinical heterogeneity, we did not analyse the data. Number of relapses in the probiotics compared to the placebo group were 4/14 (28.6%) versus 7/15 (46.7%) in <a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a> and 15/20 (75%) versus 11/12 (91.7%) in <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>. </p> </section> <section id="CD007443-sec-0061"> <h6 class="title">Maintenance of clinical remission</h6> <p>The number of participants who remained in clinical remission, i.e. did not have a relapse, was reported in three studies. It is uncertain whether probiotics lead to a difference in maintenance of remission when compared with placebo (RR 1.16, 95% CI 0.98 to 1.37; 2 studies, 141 participants; very low‐certainty of evidence; <a href="./references#CD007443-fig-0007" title="">Analysis 1.2</a>). We downgraded the evidence three times for high risk of bias and imprecision due to wide CIs, which includes appreciable harm. One additional study with 205 participants (<a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a>), reported insufficient data for inclusion in the meta‐analysis; we did not analyse the results further. </p> <p><a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a> reported on the number of participants who remained in remission, however, the definition of the relapse suggests that the data potentially includes participants in endoscopic and clinical remission. The number of people on probiotics who remained in remission compared to those on placebo were 5/20 (25%) versus 1/12 (8.3%), respectively. </p> </section> </section> <section id="CD007443-sec-0062"> <h5 class="title">Secondary outcomes</h5> <section id="CD007443-sec-0063"> <h6 class="title">Serious adverse events</h6> <p>In four studies with 351 participants which reported on serious adverse events, no events were recorded (<a href="./references#CD007443-fig-0008" title="">Analysis 1.3</a>, <a href="#CD007443-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD007443-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.3 Serious adverse events." data-id="CD007443-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.3 Serious adverse events. </p> </div> </div> </div> </section> <section id="CD007443-sec-0064"> <h6 class="title">Withdrawal due to adverse events</h6> <p>Two studies with 113 participants indicated that there were no withdrawals as a result of adverse events (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>; <a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a>). </p> </section> <section id="CD007443-sec-0065"> <h6 class="title">Need for additional therapy</h6> <p>This outcome was not reported.</p> </section> <section id="CD007443-sec-0066"> <h6 class="title">Health‐related quality of life</h6> <p>Health‐related quality of life was reported in two studies and measured using the inflammatory bowel disease questionnaire (IBD‐Q) scale in one of them (<a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a>), and the UK IBD‐Q in the other one (<a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a>). The IBD‐Q scale ranges from 1 to 7, with a higher score representing better quality of life. We found low‐certainty evidence that, on average, probiotics made no clear difference in health‐related quality of life compared with placebo (mean difference (MD) ‐0.70, 95% CI ‐1.63 to 0.23; 1 study, 25 participants; low‐certainty evidence; <a href="./references#CD007443-fig-0010" title="">Analysis 1.5</a>). We downgraded the evidence twice for imprecision due to inadequate sample size from a single study with wide CIs. The UK IBD‐Q is similar, however, the authors that used it reported separately on the five overall parameters of the questionnaire (emotional symptoms, bowel function‐1, social function, bowel function‐2, systemic function). As there was no overall score reported, we could not include a quality of life value in our meta‐analysis. </p> </section> </section> </section> <section id="CD007443-sec-0067"> <h4 class="title">Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine)</h4> <p>Three trials compared probiotics with 5‐ASA (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). See <a href="./full#CD007443-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD007443-sec-0068"> <h5 class="title">Primary outcome</h5> <section id="CD007443-sec-0069"> <h6 class="title">Clinical relapse</h6> <p>We found low‐certainty evidence that, on average, there was no clear difference in the incidence of relapse between probiotics and 5‐ASA (RR 1.01, 95% CI 0.84 to 1.22; 2 studies, 452 participants; low‐certainty evidence; <a href="./references#CD007443-fig-0011" title="">Analysis 2.1</a>). We downgraded the evidence twice for high risk of bias and imprecision due to the inadequate sample size. </p> <p>In <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>, relapse was defined "by clinical and endoscopic features". Due to the heterogeneity, we decided not to analyse the data. The number of relapses in the probiotics versus placebo group were 2/12 (16.7%) versus 2/10 (20%), respectively. </p> </section> <section id="CD007443-sec-0070"> <h6 class="title">Maintenance of clinical remission</h6> <p>We found low‐certainty evidence that, on average, probiotics showed no clear difference in maintenance of clinical remission when compared with 5‐ASA (RR 1.06, 95% CI 0.90 to 1.25; 1 study, 125 participants; low‐certainty evidence; <a href="./references#CD007443-fig-0012" title="">Analysis 2.2</a>). We downgraded the evidence twice for high risk of bias and imprecision due to a small number of events. </p> </section> </section> <section id="CD007443-sec-0071"> <h5 class="title">Secondary outcomes</h5> <section id="CD007443-sec-0072"> <h6 class="title">Serious adverse events</h6> <p>It is uncertain whether probiotics lead to a difference in serious adverse events when compared with 5‐ASA (RR 1.19, 95% CI 0.41 to 3.46; 1 study, 327 participants; very low‐certainty evidence; <a href="./references#CD007443-fig-0013" title="">Analysis 2.3</a>). We downgraded the evidence three times for high risk of bias and imprecision due to the small number of events and wide confidence interval, which includes appreciable harm. </p> </section> <section id="CD007443-sec-0073"> <h6 class="title">Withdrawal due to adverse events</h6> <p>It is uncertain whether probiotics lead to a difference in serious adverse events when compared with 5‐ASA (RR 1.02, 95% CI 0.46 to 2.25; 1 study, 222 participants; very low‐certainty evidence; <a href="./references#CD007443-fig-0014" title="">Analysis 2.4</a>). We downgraded the evidence three times for high risk of bias and imprecision due to the small number of events in a single study and wide confidence interval, which includes appreciable harm. </p> </section> <section id="CD007443-sec-0074"> <h6 class="title">Need for additional therapy</h6> <p>This outcome was not reported.</p> </section> <section id="CD007443-sec-0075"> <h6 class="title">Health‐related quality of life</h6> <p>One study reported quality of life scores at 12 months based on the IBDQ scale, ranging from 0 to 32, with a higher score representing a better quality of life (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>). We found low‐certainty evidence that there was no clear difference in health‐related quality of life between probiotics and 5‐ASA (MD ‐0.80, 95% CI ‐2.01 to 0.41; 1 study, 222 participants; low‐certainty evidence <a href="./references#CD007443-fig-0015" title="">Analysis 2.5</a>). We downgraded the evidence twice for high risk of bias and imprecision due to small sample size. </p> </section> </section> </section> <section id="CD007443-sec-0076"> <h4 class="title">Probiotic + 5‐ASA (mesalazine) versus 5‐ASA (mesalazine)</h4> <p>Four trials compared a probiotic plus 5‐ASA with 5‐ASA alone (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>; <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>; <a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). See <a href="./full#CD007443-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD007443-sec-0077"> <h5 class="title">Primary outcome</h5> <section id="CD007443-sec-0078"> <h6 class="title">Clinical relapse</h6> <p>It is uncertain whether probiotics combined with 5‐ASA leads to a difference in the incidence of relapse when compared with 5‐ASA alone (RR 1.11, 95% CI 0.66 to 1.87; 2 studies, 242 participants; very low‐certainty evidence; <a href="./references#CD007443-fig-0016" title="">Analysis 3.1</a>). We downgraded the evidence three times for high risk of bias and imprecision due to the small number of events and confidence interval, which includes appreciable benefit or harm. </p> <p>In <a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a>, relapse was defined "by clinical and endoscopic features". Due to the heterogeneity, we were unable to analyse the data. The number of relapses which occurred in the probiotics and 5‐ASA group compared to 5‐ASA alone was 4/14 (28.6%) versus 2/10 (20%). </p> </section> <section id="CD007443-sec-0079"> <h6 class="title">Maintenance of clinical remission</h6> <p>The number of participants who remained in remission, i.e. did not have a relapse, was reported in two studies. We found low‐certainty evidence that, on average, probiotics combined with and 5‐ASA showed no clear difference in maintenance of remission compared with 5‐ASA alone (RR 1.05, 95% CI 0.89 to 1.24; 1 study, 122 participants; <a href="./references#CD007443-fig-0017" title="">Analysis 3.2</a>). We downgraded the evidence twice for high risk of bias and imprecision due to the small number of events. </p> </section> </section> <section id="CD007443-sec-0080"> <h5 class="title">Secondary outcomes</h5> <section id="CD007443-sec-0081"> <h6 class="title">Serious adverse events</h6> <p>This outcome was not reported.</p> </section> <section id="CD007443-sec-0082"> <h6 class="title">Withdrawal due to adverse events</h6> <p>It is uncertain whether probiotics combined with 5‐ASA leads to a difference in withdrawal due to adverse events compared with 5‐ASA alone because the certainty of the evidence is very low. One study reported there were no withdrawals due to adverse events and one study reported two withdrawals in the probiotics combined with 5‐ASA group (RR 5.29, 95% CI 0.26 to 107.63; 2 studies, 127 participants; very low‐certainty evidence; <a href="./references#CD007443-fig-0018" title="">Analysis 3.3</a>). We downgraded the evidence three times for unclear risk of selection bias, small number of events and wide confidence interval, which includes appreciable harm. </p> </section> <section id="CD007443-sec-0083"> <h6 class="title">Need for additional therapy</h6> <p>This outcome was not reported.</p> </section> <section id="CD007443-sec-0084"> <h6 class="title">Health‐related quality of life</h6> <p>This outcome was not reported.</p> </section> </section> </section> <section id="CD007443-sec-0085"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses using an available case analysis versus intention‐to‐treat (ITT) analysis as well as fixed‐effect versus random‐effects models. We did not find any differences between either set of analyses. See full data in <a href="#CD007443-tbl-0005">Table 2</a>. </p> <div class="table" id="CD007443-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fixed‐effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Random‐effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Probiotics versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.85, 95% CI 0.68 to 1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.87, 95% CI 0.63 to 1.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintenace of clinical remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.16, 95% CI 0.98 to 1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11, 95% CI 0.99 to 1.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Probiotics versus 5‐ASA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.00, 95% CI 0.83 to 1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01, 95% CI 0.84 to 1.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintenace of clinical remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.06, 95% CI 0.90 to 1.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.06, 95% CI 0.90 to 1.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Probiotics + 5‐ASA versus 5‐ASA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.10, 95% CI 0.69 to 1.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11, 95% CI 0.66 to 1.87</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintenance of clinical remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05, 95% CI 0.89 to 1.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05, 95% CI 0.89 to 1.24</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>5‐ASA</b> : 5‐aminosalicylic acid; <b>CI</b> : confidence interval; <b>RR</b>: risk ratio </p> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007443-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007443-sec-0086"></div> <section id="CD007443-sec-0087"> <h3 class="title" id="CD007443-sec-0087">Summary of main results</h3> <p>This review included 11 parallel group randomised controlled trials (RCTs) assessing the effectiveness of probiotics for the maintenance of remission in ulcerative colitis. All the studies, except two (<a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a>; <a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a>), provided sufficient data for inclusion in a meta‐analysis. The comparisons assessed by the studies were probiotics versus placebo, probiotics versus 5‐aminosalicylic acid (5‐ASA) and probiotic plus 5‐ASA versus 5‐ASA. We analysed and summarised data from nine studies (1031 participants): <a href="./full#CD007443-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD007443-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD007443-tbl-0003">summary of findings Table 3</a>. It is uncertain if there is any difference in occurrence of clinical relapse when probiotics are compared with placebo (very low‐certainty evidence). When probiotics were compared with 5‐ASA, there was no clear difference in relapse (low‐certainty evidence). It is uncertain whether probiotics lead to a difference in maintenance of remission when compared with placebo because the certainty of the evidence is very low. There is no clear difference in maintenance of remission when probiotics are compared with 5‐ASA, neither is there a difference when probiotics combined with 5‐ASA is compared with 5‐ASA alone (low‐certainty evidence). It is uncertain whether probiotics combined with 5‐ASA leads to a difference in the incidence of relapse when compared with 5‐ASA alone because the certainty of the evidence is very low. </p> <p>The studies comparing probiotics with placebo reported that no serious adverse events occurred. One study comparing probiotics and 5‐ASA reported on similar numbers of serious adverse events in both groups. Further details were not provided on these serious adverse events. </p> <p>No difference in efficacy was found between probiotics and placebo, which could reflect the clinical truth of no efficacy regarding these agents. However, no difference was found between probiotics and 5‐ASA either. This is key, as 5‐ASA are generally used as standard first‐line interventional therapy, with their efficacy well demonstrated in previous systematic reviews (<a href="./references#CD007443-bbs2-0079" title="WangY , ParkerCE , FeaganBG , MacDonaldJK . Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD000544.pub4]">Wang 2016</a>). As such, given the lack of efficacy of probiotics compared with placebo, it would be expected that they would be inferior to 5‐ASA as standard therapy, which has not been demonstrated. We do not have enough evidence in this current synthesis to demonstrate the efficacy of probiotics, but feel these inconsistencies raise genuine questions for clinicians, researchers and users in the field. </p> </section> <section id="CD007443-sec-0088"> <h3 class="title" id="CD007443-sec-0088">Overall completeness and applicability of evidence</h3> <p>The capricious body of evidence synthesised in this review is highly heterogenous in terms of population and intervention, and as such, significantly limits its applicability to guide decision making. In considering application of the evidence, clinicians and patients require not just statistically significant results; the results need to reflect specific clinical contexts and problems for which they can apply these solutions. It is particularly striking that on updating this review after almost 10 years, the body of evidence has grown but is still far from complete and unable to be applied to practice. </p> <p>The studies involved a wide range of people who had been in remission for various lengths (&gt; 1 month to 12 years), but as recruiting studies ubiquitously made such judgements on clinical grounds, with the addition of activity scores, consideration of concepts, such as 'deep remission', which are key in practice, is completely absent from the discourse in these trials. The weaknesses of the primary studies have not allowed exploration of such wide ranging participant characteristics through subgroup analysis, which would be key for implementation of any findings from such a review. </p> <p>There was minimal consideration of children in included studies, with all except <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a> recruiting only adults. Based on its inclusion criteria, <a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a> attempted to recruit both adult and paediatric patients, but it is not clear if they actually achieved this, treating them as one population. As such, the applicability of this evidence to paediatric patients is a significant concern. Furthermore, almost half of the studies excluded participants who were receiving immunosuppressants at the point of recruitment, suggesting a preference for people with mild disease severity. This should be considered in applying the evidence in practice. </p> <p>Study participants received probiotics which had either single or multiple strains for a maximum period of 12 to 52 weeks. Whilst it is common for reviews within Cochrane and the wider field to synthesis evidence that considers probiotics as a single interventional group, subgroup analysis is key for what are effectively a disparate family of interventional agents, and once again the limitations of the evidence in this review has not allowed this to be completed. </p> <p>Relapse and maintenance of remission were reported in most of the studies. However, most of the secondary outcomes were not sufficiently reported. Serious adverse events were reported, however, this outcome was not described at all in any of the studies. Health‐related quality of life and withdrawal due to adverse events were rarely reported. Need for withdrawal of therapy was not reported in any of the included studies. The effect of probiotics on these secondary outcomes remains unclear. </p> </section> <section id="CD007443-sec-0089"> <h3 class="title" id="CD007443-sec-0089">Certainty of the evidence</h3> <p>The certainty of evidence was either low or very low due to risk of bias and imprecision. Eight studies were at high risk of bias and three studies were at unclear risk of bias. Most of the studies failed to provide sufficient information on allocation concealment. Though the studies which used double‐blinding had clearly included placebo or provided control which was identical to the study intervention to prevent performance bias, it was not explicitly stated whether outcome assessment was blinded or not. Indicating that a study was double‐blinded without explicitly stating who (participants, caregiver, outcome assessor, etc.) the blinding was applied to is usually not helpful in 'Risk of bias' assessment. Five studies were published as abstracts and were at unclear risk of bias for most domains. </p> <p>The studies had sample sizes of between 25 and 327 participants. We downgraded for imprecision as the trials either had small numbers of events or small sample sizes which were insufficient to meet the optimal information size, thus resulting in wide confidence intervals. Whilst power calculations were used, they were often based on estimates of effect, rather than previous trial data, and therefore this raises the question as to whether these studies were adequately powered. The definition of relapse reported in some of the studies suggests that people with endoscopic and clinical relapse or remission may have been lumped together. We carried out a narrative synthesis of such studies since they were dissimilar to the studies which clearly reported on clinical relapse only. This reduced the amount of data that were pooled for the outcome of clinical relapse/remission and increased imprecision. </p> <p>Most of the analyses involved single studies. Where there was sufficient data for pooling, there was no heterogeneity (I<sup>2</sup> = 0%). Therefore, there was no reason to downgrade for inconsistency. </p> <p>There was no indirectness, as the included studies all addressed the objectives of the review and fit within the scope. The number of studies included in the meta‐analysis was insufficient to assess for publication bias. </p> <p>The inconsistency within results has already been discussed, with no difference between probiotics and placebo nor probiotics and 5‐ASA (a standard treatment with proven superiority over placebo). This point is highlighted in the context of the quality issues raised, given that all but one study comparing probiotics and placebo was at high risk of bias. It is therefore likely that this is the source of the inconsistency and is a key message for future researchers. </p> </section> <section id="CD007443-sec-0090"> <h3 class="title" id="CD007443-sec-0090">Potential biases in the review process</h3> <p>We are aware of the biases that could arise from missing data and made efforts to contact authors for additional information and clarifications. However, most of the authors we contacted failed to reply. To minimise bias, we included such studies in our narrative synthesis and carried out sensitivity analyses, where possible, to provide a conservative estimate of effect. We aim to include any data which become available from authors in future updates. </p> <p>Other limitations in the review process are to do with risk of bias of individual studies. Three of the included studies are only available as abstracts. This meant that the studies had to be marked at unclear risk of bias for most of the domains. Given that we did not carry out sensitivity analyses to examine their impact on the results due to the insufficient number of studies included in each meta‐analysis, the inclusion of these abstracts may further influence the validity of the data. </p> <p>Finally, we are aware of the possible impact of industry funding on the validity of trial results. Funding from probiotic manufacturing companies or inclusion of company staff in the author team was noted in some of the studies and we considered the impact of this information on the 'Risk of bias' assessment of the studies and GRADE assessment of the evidence. Given that none of the studies showed a clear difference in favour of probiotics, we assumed that industry funding is unlikely to have compromised the results of this review. </p> </section> <section id="CD007443-sec-0091"> <h3 class="title" id="CD007443-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>There is currently no other known evidence‐based guidance or systematic review around the use of probiotics for the maintenance of remission in ulcerative colitis, apart from the previous version of this review (<a href="./references#CD007443-bbs2-0081" title="NaidooK , GordonM , FagbemiAO , ThomasAG , AkobengAK . Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2011, Issue 12. [DOI: 10.1002/14651858.CD007443.pub2]">Naidoo 2011</a>). The European Crohn's and Colitis Organisation (ECCO) and European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPHGAN) guideline briefly described the evidence on the efficacy of probiotics and made no recommendation regarding its use for the maintenance of remission (<a href="./references#CD007443-bbs2-0077" title="TurnerD , RuemmeleFM , Orlanski-MeyerE , GriffithsAM , deCarpiJM , BronskyJ , et al. Management of paediatric ulcerative colitis, Part 1: ambulatory care—an evidence-based guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;67(2):257-91. [DOI: 10.1097/mpg.0000000000002035]">Turner 2018</a>). The current National Institute for Health and Care Excellence (NICE) guideline does not cover probiotics either (NICE 2013). This review has found insufficient evidence on the effect of probiotics for maintenance of remission in ulcerative colitis, and therefore retains the same conclusion from <a href="./references#CD007443-bbs2-0081" title="NaidooK , GordonM , FagbemiAO , ThomasAG , AkobengAK . Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2011, Issue 12. [DOI: 10.1002/14651858.CD007443.pub2]">Naidoo 2011</a>. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007443-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007443-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007443-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007443-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.1 Clinical relapse." data-id="CD007443-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.1 Clinical relapse.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.3 Serious adverse events." data-id="CD007443-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 1: Clinical relapse" data-id="CD007443-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 1: Clinical relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 2: Maintenance of clinical remission" data-id="CD007443-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 2: Maintenance of clinical remission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 3: Serious adverse events" data-id="CD007443-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 4: Withdrawal due to adverse events" data-id="CD007443-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 4: Withdrawal due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Probiotics versus placebo, Outcome 5: Health‐related quality of life" data-id="CD007443-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Probiotics versus placebo, Outcome 5: Health‐related quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 1: Clinical relapse" data-id="CD007443-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 1: Clinical relapse </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 2: Maintenance of clinical remission" data-id="CD007443-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 2: Maintenance of clinical remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 3: Serious adverse events" data-id="CD007443-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 4: Withdrawal due to adverse events" data-id="CD007443-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 4: Withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 5: Health‐related quality of life" data-id="CD007443-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine), Outcome 5: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine), Outcome 1: Clinical relapse" data-id="CD007443-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine), Outcome 1: Clinical relapse </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine), Outcome 2: Maintenance of clinical remission" data-id="CD007443-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine), Outcome 2: Maintenance of clinical remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007443-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/urn:x-wiley:14651858:media:CD007443:CD007443-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine), Outcome 3: Withdrawal due to serious adverse events" data-id="CD007443-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_t/tCD007443-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine), Outcome 3: Withdrawal due to serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/media/CDSR/CD007443/image_n/nCD007443-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007443-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Probiotics compared to placebo for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotics compared to placebo for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with ulcerative colitis in remission<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> probiotics<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotics</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse</p> <p>(12 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/>(0.63 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>361<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse was defined as a flare‐up (NCT02361957), CAI ≤ 5 (Yasushi 2015) and persistence of a rectal bleeding score of ≤ 2 on Sutherland DAI score for 3 consecutive days and/or initiation of remission induction therapy for worsening of ulcerative colitis (Matsuoka 2018), respectively </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>554 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>493 per 1000<br/>(399 to 609) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of clinical remission</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/>(0.98 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>141<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of remission is the number of participants who did not relapse. One additional study reported insufficient data for inclusion in the meta‐analysis, therefore, we did not further analyse the results (reported P = 0.643). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>532 per 1000<br/>(308 to 924) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(48 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four studies reported that no serious adverse events occurred.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies reported there were no withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for additional therapy</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean IBD‐Q score with placebo was 3.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.70 points lower<br/>(1.63 lower to 0.23 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scale: IBD‐Q, range 1 ‐7, higher score = better quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CAI</b> : colitis activity index <b>CI:</b> confidence interval; <b>DAI</b> : disease activity index; <b>IBD‐Q</b> : inflammatory bowel disease questionnaire; <b>MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three times: risk of reporting bias and other bias due to imbalance in baseline characteristics, imprecision due to small sample size.<br/><sup>b</sup>Downgraded two times: imprecision due to small sample size from a single study resulting in wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Probiotics compared to placebo for maintenance of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007443-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotics compared to 5‐ASA (mesalazine) for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with ulcerative colitis in remission<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> probiotics<br/><b>Comparison:</b> 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotics</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.84 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>452<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse was based on the presence of all the following: CAI &gt; 6 (or an increase in CAI of at least 3 points with CAI = 4 being exceeded at the same time); endoscopic index &gt; 4; histological signs of acute inflammation (<a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a>) and appearance of ulcerative colitis symptoms or an increase in CAI to more than 4 points (<a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000<br/>(380 to 554) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of clinical remission</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/>(0.90 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of remission is the number of participants who did not relapse.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>848 per 1000<br/>(720 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/>(0.41 to 3.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>327<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events were not reported in detail</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000<br/>(15 to 126) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> <p>(52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.46 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>222<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Discontinuation of therapy was due to gastrointestinal disorders, such as bloody stools, nausea, diarrhoea, mucous secretion and abdominal pain </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/>(45 to 221) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for additional therapy</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> <p>(52 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean IBD‐Q score with 5‐ASA was 24.3 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 0.80 points lower (2.01 lower to 0.41 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scale: IBD‐Q, range 1 ‐32, higher score = better quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>5‐ASA</b> : 5‐aminosalicylic acid; <b>CAI</b> : colitis activity index <b>CI:</b> confidence interval; <b>IBD‐Q</b> : inflammatory bowel disease questionnaire; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two times: risk of attrition bias and other bias due to imbalance in baseline characteristics, imprecision due to sample size not meeting the optimal information size.<br/><sup>b</sup>Downgraded two times: risk of performance and detection bias from an open‐label study and small number of events.<br/><sup>c</sup>Downgraded two times: risk of attrition bias and imprecision due to small sample size.<br/><sup>d</sup>Downgraded three times: risk of attrition bias, imprecision due to small number of events from a single study resulting in wide confidence interval which includes appreciable harm. Serious adverse events were not described in detail.<sup>e</sup>Downgraded three times: risk of attrition bias, imprecision due to small number of events from a single study resulting in wide confidence interval which includes appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for maintenance of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007443-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐ASA (mesalazine) for maintenance of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Probiotic + 5‐ASA (mesalazine) compared to 5‐ASA (mesalazine) for maintenance of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with ulcerative colitis in remission<br/><b>Setting:</b> hospitals<br/><b>Intervention:</b> probiotic + 5‐ASA<br/><b>Comparison:</b> 5‐ASA </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic + 5‐ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse</p> <p>(12 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.66 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>242<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> l<b>ow<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse was defined as CAI &gt; 4 (<a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a>) and appearance of ulcerative colitis symptoms or an increase in CAI to more than 4 points (<a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1000<br/>(144 to 371) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of clinical remission</p> <p>(24 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/>(0.89 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>122<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance of clinical remission is the number of participants who did not relapse.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>840 per 1000<br/>(712 to 992) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse events</p> <p>(12 to 52 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.29</p> <p>(0.26 to 107.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> l<b>ow<sup>c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two discontinuations in the probiotic arm were due to avascular necrosis of bilateral femoral head and pulmonary thromboembolism. </p> <p>One study (n = 24) reported no events in either arm.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for additional therapy</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>5‐ASA</b> : 5‐aminosalicylic acid; CAI: Colitis activity index <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three times: risk of attrition bias, imprecision due to small number of events and confidence interval which includes appreciable harm.<br/><sup>b</sup>Downgraded two times: risk of performance and detection bias from an open‐label study, imprecision due to small number of events.<br/><sup>c</sup>Downgraded three times: unclear risk of selection bias (lack of information on sequence generation), imprecision due to small number of events in a single study and confidence interval which include appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐ASA (mesalazine) for maintenance of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007443-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome data table</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of relapses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition of relapse</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Maintenance of remission</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of life</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Withdrawal due to adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0001" title="BjarnasonI , SissionG , HayeeB . A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology2019;27:465-73. ">Bjarnason 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 versus 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 +/‐ 2.8 versus 8.0 +/‐ 2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0006" title="NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. ">NCT02361957</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13 versus 1/12;</p> <p>0/13 versus 2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse was defined as a flare‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 +/‐ 0.7 versus 4.2 +/‐ 1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0002" title="CopaciI , ChiriacG . Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal2014;1:A375. ">Copaci 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30% versus 28%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77% versus 90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0003" title="KruisW , SchutzE , FricP , FixaB , JudmaierG , StolteM . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics1997;11(5):853-8. ">Kruis 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/50 versus 6/53;</p> <p>18/60 versus 13/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAI &gt; 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/50 versus 1/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0004" title="KruisW , FricP , PokrotnieksJ , LukasM , FixaB , KascakM , et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut2004;53(11):1617-23. ">Kruis 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/110 versus 38/112; 92/162 versus 91/165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The presence of all of the following: CAI &gt; 6 (or an increase in CAI of at least 3 points with CAI = 4 being exceeded at the same time); endoscopic index &gt; 4; histological signs of acute inflammation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3 +/‐ 5.2 versus 25.1 +/‐ 3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/162 versus 6/165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/110 versus11/112; 63/162 versus 64/165</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0005" title="MatsuokaK , UemuraY , KanaiT . Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences2018;ns:1-10. [org/10.1007/s10620-018-4946-2]">Matsuoka 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/97 versus 19/95</p> <p>55/98 versus 58/97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The persistence of a rectal bleeding score of ≥ 2 on Sutherland DAI score for 3 consecutive days and/or initiation of remission induction therapy for worsening of UC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported P = 0.643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/97 versus 2/95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0007" title="ShanahanF , GuarnerF , Von WrightA , Vilpponen-SalmelaT , O'Donoghue, D, KielyB , et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology2006;130(4 Suppl 2):A44. ">Shanahan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as &lt; 3 bowel movements per day (without frank/gross blood) out of 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0008" title="VejdaniR , BahariA , ZadehAM , AzmiM , Ebrahimi-DaryaniN , HashtroudiAA , et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. ">Vejdani 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/14 versus 4/15;</p> <p>4/14 versus 7/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An increase in bowel frequency with blood for at least 1 week. A colonoscopy was performed and biopsies were taken to confirm relapse </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0009" title="WildtS , NordgaardI , HansenU , BrockmannE , RumessenJJ . A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis2011;5(2):115-21. ">Wildt 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/20 versus 11/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCCAI score &gt; 4 and/or endoscopic changes grade 2–3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/20 versus 1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 versus 0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 versus 0/12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0010" title="YasushiY , AkihiroY , RyuichiF , KojiS , AisakuO , KentaroN , et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology2015;21(19):5985-94. ">Yasushi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/23 versus 10/23;</p> <p>14/30 versus 17/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAI ≤ 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/23 versus 13/23</p> <p>16/30 versus 13/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/23 versus 0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0011" title="ZoccoMA , dal VermeLZ , ArmuzziA , NistaEC , PapaA , CandelliM . Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology2003;124(4):A201. ">Zocco 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/12 versus 2/10 versus 4/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined by clinical and endoscopic features</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/12 versus 0/10 versus 0/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007443-bbs2-0012" title="ZoccoMA , dal VermeLZ , CremoniniF , PiscagliaAC , NistaEC , CandelliM , et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;23(11):1567-74. ">Zocco 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/65 (Probiotic) versus 12/60 (Mesalazine) versus 10/62 (Probiotic+Mesalazine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The appearance of UC symptoms or an increase in CAI to more than 4 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/65 versus 48/60 versus 52/62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/65 versus 0/60 versus 0/62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Serious adverse events which occurred were reportedly not related to the intervention (avascular necrosis of bilateral femoral head and pulmonary thromboembolism) </p> <p>CAI: colitis activity index; DAI: disease activity index; NR: not reported; SCCAI: simple clinical colitis activity index UC: ulcerative colitis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome data table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007443-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fixed‐effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Random‐effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Probiotics versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.85, 95% CI 0.68 to 1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.87, 95% CI 0.63 to 1.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintenace of clinical remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.16, 95% CI 0.98 to 1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11, 95% CI 0.99 to 1.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Probiotics versus 5‐ASA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.00, 95% CI 0.83 to 1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01, 95% CI 0.84 to 1.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintenace of clinical remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.06, 95% CI 0.90 to 1.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.06, 95% CI 0.90 to 1.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Probiotics + 5‐ASA versus 5‐ASA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.10, 95% CI 0.69 to 1.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.11, 95% CI 0.66 to 1.87</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintenance of clinical remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05, 95% CI 0.89 to 1.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05, 95% CI 0.89 to 1.24</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><b>5‐ASA</b> : 5‐aminosalicylic acid; <b>CI</b> : confidence interval; <b>RR</b>: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/full#CD007443-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007443-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Probiotics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Clinical relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.63, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Maintenance of clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.98, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.63, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Probiotics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007443-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Clinical relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Maintenance of clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.90, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.41, 3.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.46, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.01, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Probiotics versus 5‐aminosalicylic acid (5‐ASA) (mesalazine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007443-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Clinical relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.66, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Maintenance of clinical remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.89, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Withdrawal due to serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.29 [0.26, 107.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) versus 5‐ASA (mesalazine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007443.pub3/references#CD007443-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007443.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007443-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007443-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007443-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD007443-note-0013">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD007443-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007443-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD007443-note-0011">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007443-note-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007443-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007443\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007443\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007443\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007443\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007443\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007443.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007443.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007443.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007443.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007443.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726624551"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007443.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726624555"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007443.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9833ead5f3c9',t:'MTc0MDcyNjYyNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 